viewMotus GI

Motus GI says sales force expanded before launch of Pure-Vu colonoscopy system

The medical technology company says that since its February 2018 IPO, it has begun a marketing program to drive momentum for Pure-Vu

An illustration for medicine
Pure-Vu is a FDA-cleared device designed to make colonoscopy more cost-efficient

Motus GI Holdings Inc (NASDAQ:MOTS) cited Wednesday in its 2018 financial statement the expansion of its sales force in anticipation of the full commercial launch of its Pure-Vu colonoscopy system.

The medical technology company said that since its February 2018 initial public offering, it has begun a marketing program to drive momentum before the launch.

Pure-Vu System, according to Fort Lauderdale, Florida-based Motus GI, is a medical device cleared by the Food and Drug Administration designed to reduce costs by facilitating the cleaning of a poorly prepped colon during colonoscopy procedures.

READ: VolitionRx's market in cancer detection expanding sharply with its Nu.Q product, says Maxim

Motus GI added that it plans to submit a notice to the FDA for the second generation of Pure-Vu in the first half of 2019. It also plans to present findings of its Reliable Endoscopic Diagnosis Utilizing Cleansing Enhancement (REDUCE) at conferences.

"The statistically significant interim data from the REDUCE study, conducted in real-world settings and generating clinical experience with important thought leaders in our field, solidifies our belief that our revolutionary Pure-Vu System technology will not only allow physicians to improve the time associated with completing a high-quality, successful colonoscopy, but will also provide hospitals with a potential solution for improving the total cost of care,” Motus GI CEO Tim Moran said in a statement.

Year-end cash

The company said it ended 2018 with cash and cash equivalents and short-term investments of about $21.1 million.

For the year, Motus GI reported a net loss of $22.3 million, or $1.47 per diluted share, including a one-time, non-cash warrant expense charge of $3.2 million. That compares with a net loss of $13.2 million, or $1.28 per diluted share, a year earlier. 

Shares slipped $0.05 to $3.90 in Wednesday’s Nasdaq trading.

Contact Dennis Fitzgerald at [email protected]

Quick facts: Motus GI

Price: 1.3 USD

Market: NASDAQ
Market Cap: $37.47 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Medexus Pharmaceuticals pleased with recent Aptevo BioTherapeutics...

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQB:PDDPF) CEO Ken d’Entremont tells Proactive he's pleased with the value the acquisition of hematology asset IXINITY has provided to Medexus, and that it is well positioned to emerge stronger when the economy reopens after the coronavirus crisis....

20 minutes ago

2 min read